Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N. Badiyan; Michael C. Roach; Michael D. Chuong; Stephanie R. Rice; Nasarachi E. Onyeuku; Jill Remick; Srinivas Chilukuri; Erica Glass; Pranshu Mohindra; Charles B. Simone

doi:10.21037/jtd.2018.05.73

Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N. Badiyan, Michael C. Roach, Michael D. Chuong, Stephanie R. Rice, Nasarachi E. Onyeuku, Jill Remick, Srinivas Chilukuri, Erica Glass, Pranshu Mohindra, Charles B. Simone

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

Original language	English
Pages (from-to)	S2492-S2507
Journal	Journal of Thoracic Disease
Volume	10
DOIs	https://doi.org/10.21037/jtd.2018.05.73
State	Published - Aug 1 2018

Keywords

Esophageal cancer
Immune checkpoint inhibitors (ICIs)
Immunotherapy
Lung cancer
Mesothelioma
Radiation therapy (RT)
Thymoma

Access to Document

10.21037/jtd.2018.05.73

Cite this

@article{5f908c37eca64d809be8d8fdf70a4981,

title = "Combining immunotherapy with radiation therapy in thoracic oncology",

abstract = "Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.",

keywords = "Esophageal cancer, Immune checkpoint inhibitors (ICIs), Immunotherapy, Lung cancer, Mesothelioma, Radiation therapy (RT), Thymoma",

author = "Badiyan, {Shahed N.} and Roach, {Michael C.} and Chuong, {Michael D.} and Rice, {Stephanie R.} and Onyeuku, {Nasarachi E.} and Jill Remick and Srinivas Chilukuri and Erica Glass and Pranshu Mohindra and Simone, {Charles B.}",

note = "Publisher Copyright: {\textcopyright} Journal of Thoracic Disease.",

year = "2018",

month = aug,

day = "1",

doi = "10.21037/jtd.2018.05.73",

language = "English",

volume = "10",

pages = "S2492--S2507",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

}

TY - JOUR

T1 - Combining immunotherapy with radiation therapy in thoracic oncology

AU - Badiyan, Shahed N.

AU - Roach, Michael C.

AU - Chuong, Michael D.

AU - Rice, Stephanie R.

AU - Onyeuku, Nasarachi E.

AU - Remick, Jill

AU - Chilukuri, Srinivas

AU - Glass, Erica

AU - Mohindra, Pranshu

AU - Simone, Charles B.

N1 - Publisher Copyright: © Journal of Thoracic Disease.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

AB - Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

KW - Esophageal cancer

KW - Immune checkpoint inhibitors (ICIs)

KW - Immunotherapy

KW - Lung cancer

KW - Mesothelioma

KW - Radiation therapy (RT)

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=85051252947&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.05.73

DO - 10.21037/jtd.2018.05.73

M3 - Review article

C2 - 30206494

AN - SCOPUS:85051252947

SN - 2072-1439

VL - 10

SP - S2492-S2507

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

ER -

Combining immunotherapy with radiation therapy in thoracic oncology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this